Adenoviral Vectors in Gene Therapy: A Detailed Overview

Saber, Hamidreza; Mousavipour, Zahra

doi:10.61882/ibj.5062

Volume 30, Issue 1 (1-2026) IBJ 2026, 30(1): 16-35 | Back to browse issues page

‎ 10.61882/ibj.5062

PMID: 42159668

Mendeley

Zotero

RefWorks

Saber H, Mousavipour Z. Adenoviral Vectors in Gene Therapy: A Detailed Overview. IBJ 2026; 30 (1) :16-35
URL: http://ibj.pasteur.ac.ir/article-1-5062-en.html

Adenoviral Vectors in Gene Therapy: A Detailed Overview

Hamidreza Saber ^*

, Zahra Mousavipour

Abstract:

Adenoviral vectors (AdVs) represent one of the most extensively researched platforms in the realm of gene therapy, providing advantages such as high transduction efficiency, large transgene capacity, and broad tropism. This review provides a detailed and structured overview of AdVs, highlighting their biology, gene delivery mechanisms, clinical applications, and challenges limiting their broader therapeutic applicability. The study also explores recent progress in vector engineering, such as rare serotypes, capsid modifications, third-generation vectors, as well as strategies for immune modulation and toxicity reduction. AdVs are used in therapies for genetic disorders, oncology, and vaccinology, alongside innovations such as CRISPR-Cas9, nanotechnology, and artificial intelligence design. Nevertheless, persistent hurdles, including vector immunogenicity, hepatotoxicity, scalability, and the lack of durable expression, prevent widespread clinical use. This review consolidates current knowledge and presents a future perspective on how AdVs may evolve as powerful, adaptable, and precise tools in modern gene therapy. By contextualizing strengths and unresolved challenges, this work aims to give researchers and clinicians a balanced foundation for evaluating their future roles in translational medicine.

Keywords: Adenoviridae, Genetic therapy, Oncolytic virotherapy, Transgene

Full-Text [PDF 935 kb]

Type of Study: Review Article | Subject: Molecular Genetics & Genomics

References

1. Dong H. Advances in experimental medicine and biology. Springer Nature;2023.

2. Solinís MÁ, del Pozo-Rodríguez A, Apaolaza PS, Rodríguez-Gascón A. Treatment of ocular disorders by gene therapy. Eur J Pharm Biopharm. 2015:95:331-42. [DOI:10.1016/j.ejpb.2014.12.022]

3. Fichter C. Development of novel transient delivery systems for gene therapy. UNSW Sydney. 2023.

4. Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med. 1953;84(3):570-3. [DOI:10.3181/00379727-84-20714]

5. Dhingra A, Hage E, Ganzenmueller T, Böttcher S, Hofmann J, Hamprecht K, et al. Molecular evolution of human adenovirus (HAdV) species C. Sci Rep. 2019;9(1):1039. [DOI:10.1038/s41598-018-37249-4]

6. Usman N, Suarez M. Adenoviruses: StatPearls Publishing; 2023.

7. Nemerow GR, Stewart PL, Reddy VS. Structure of human adenovirus. Curr Opin Virol. 2012;2(2):115-21. [DOI:10.1016/j.coviro.2011.12.008]

8. Harrison SC. Looking inside adenovirus. Science. 2010;329(5995):1026-7. [DOI:10.1126/science.1194922]

9. Reddy VS, Natchiar SK, Stewart PL, Nemerow GR. Crystal structure of human adenovirus at 3.5A resolution. Science. 2010;329(5995):1071-5. [DOI:10.1126/science.1187292]

10. Kasala D, Yoon A-R, Hong J, Wan Kim S, Yun C-O. Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy. Nanomedicine. 2016;11(13):1689-713. [DOI:10.2217/nnm-2016-0060]

11. Shah AH, Cianciola NL, Mills JL, Sönnichsen FD, Carlin C. Adenovirus RIDα regulates endosome maturation by mimicking GTP-Rab7. J Cell Biol. 2007;179(5):965-80. [DOI:10.1083/jcb.200702187]

12. Grgić H, Yang D-H, Nagy E. Pathogenicity and complete genome sequence of a fowl adenovirus serotype 8 isolate. Virus Res. 2011;156(1-2):91-7. [DOI:10.1016/j.virusres.2011.01.002]

13. Xu Z-L, Mizuguchi H, Sakurai F, Koizumi N, Hosono T, Kawabata K, et al. Approaches to improving the kinetics of adenovirus-delivered genes and gene products. Adv Drug Deliv Rev. 2005;57(5):781-802. [DOI:10.1016/j.addr.2004.12.010]

14. Walther W, Stein U. Viral Vectors for gene transfer: A review of their use in the treatment of human diseases. Drugs. 2000;60(2):249-71. [DOI:10.2165/00003495-200060020-00002]

15. Kovesdi I, Hedley SJ. Adenoviral producer cells. Viruses. 2010;2(8):1681-703. [DOI:10.3390/v2081681]

16. Poulin KL, Clarkin RG, Del Papa J, Parks RJ. Development and characterization of an oncolytic human adenovirus-based vector co-expressing the adenovirus death protein and p14 fusion-associated small transmembrane fusogenic protein. Int J Mol Sci. 2024;25(22):12451. [DOI:10.3390/ijms252212451]

17. Park A, Lee JY. Adenoviral vector system: A comprehensive overview of constructions, therapeutic applications and host responses. J Microbiol. 2024;62(7):491-509. [DOI:10.1007/s12275-024-00159-4]

18. Leissner P, Legrand V, Schlesinger Y, Hadji DA, Raaij MV, Cusack S, et al. Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther. 2001;8(1):49-57. [DOI:10.1038/sj.gt.3301343]

19. Dautry-Varsat A. Receptor-mediated endocytosis: The intracellular journey of transferrin and its receptor. Biochimie. 1986;68(3):375-81. [DOI:10.1016/S0300-9084(86)80004-9]

20. Parvin N, Mandal TK, Joo S-W. The impact of COVID-19 on RNA therapeutics: A surge in lipid nanoparticles and alternative delivery systems. Pharmaceutics. 2024;16(11):1366. [DOI:10.3390/pharmaceutics16111366]

21. Maier O, Marvin SA, Wodrich H, Campbell EM, Wiethoff CM. Spatiotemporal dynamics of adenovirus membrane rupture and endosomal escape. J Virol. 2012;86(19):10821-8. [DOI:10.1128/JVI.01428-12]

22. Goswami R, Subramanian G, Silayeva L, Newkirk I, Doctor D, Chawla K, et al. Gene therapy leaves a vicious cycle. Front Oncol. 2019:9:297. [DOI:10.3389/fonc.2019.00297]

23. Kau TR, Silver PA. Nuclear transport as a target for cell growth. Drug Discov Today. 2003;8(2):78-85. [DOI:10.1016/S1359-6446(02)02562-X]

24. Fischer J, Kolk A, Wolfart S, Pautke C, Warnke PH, Plank C, et al. Future of local bone regeneration-protein versus gene therapy. J Craniomaxillofac Surg. 2011;39(1):54-64. [DOI:10.1016/j.jcms.2010.03.016]

25. Tessarollo NG, Domingues ACM, Antunes F, da Luz JCDS, Rodrigues OA, Cerqueira OLD, et al. Nonreplicating adenoviral vectors: Improving tropism and delivery of cancer gene therapy. Cancers. 2021;13(8):1863. [DOI:10.3390/cancers13081863]

26. Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020;14(10):12522-37. [DOI:10.1021/acsnano.0c07197]

27. Coleman WB, Tsongalis GJ. The molecular basis of human cancer. Second Edition. Springer;2017. [DOI:10.1007/978-1-59745-458-2]

28. Guzmán CA, Feuerstein GZ. Pharmaceutical biotechnology. First Edition. Springer New York; 2009. [DOI:10.1007/978-1-4419-1132-2]

29. Ricobaraza A, Gonzalez-Aparicio M, Mora-Jimenez L, Lumbreras S, Hernández-Alcoceba R. High capacity adenoviral vectors: Expanding the scope of gene therapy. Int J Mol Sci. 2020;21(10):3643. [DOI:10.3390/ijms21103643]

30. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 2006;13(11):975-92. [DOI:10.1038/sj.cgt.7700946]

31. Bernabéu-Gimeno M, Pardo-Freire M, Chan BK, Turner PE, Gil-Brusola A, Pérez-Tarazona S, et al. Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients. Med. 2024;5(9):1096-111. [DOI:10.1016/j.medj.2024.05.017]

32. Hunt KK, Vorburger SA, Swisher SG. Gene Therapy for Cancer. First Edition. Humana Press;2007. [DOI:10.1007/978-1-59745-222-9]

33. Wallace R, Bliss CM, Parker AL. The immune system-a double-edged sword for adenovirus-based therapies. Viruses. 2024;16(6):973. [DOI:10.3390/v16060973]

34. Haque US, Yokota T. Gene editing for duchenne muscular dystrophy: From experimental models to emerging therapies. Degener Neurol Neuromuscular Dis. 2025:15:17-40. [DOI:10.2147/DNND.S495536]

35. Lecomte E, Tournaire B, Cogne B, Dupont J-B, Lindenbaum P, Martin-Fontaine M, et al. Advanced characterization of DNA molecules in rAAV vector preparations by single-stranded virus next-generation sequencing. Mol Ther Nucleic Acids. 2015;4(10);260. [DOI:10.1038/mtna.2015.32]

36. Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: The status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2021:170:1-25. [DOI:10.1016/j.addr.2020.12.011]

37. Li Y, Zhang H, Xin W, Qin T. Adenoviral therapy for cervical cancer: From targeted modification to immunotherapy. Anticancer Agents Med Chem. 2025;25(14):967-77. [DOI:10.2174/0118715206338559241112060553]

38. Sampson AT, Hlaváč M, Gillman ACT, Douradinha B, Gilbert SC. Developing the next-generation of adenoviral vector vaccines. Hum Vaccin Immunother. 2025;21(1):2514356. [DOI:10.1080/21645515.2025.2514356]

39. Petrović Koshmak I, Jug H, Vrabec K, Mavri A, Novak V, Dekleva P, et al. Bridging upstream and downstream for improved adenovirus 5 bioprocess. Electrophoresis. 2024;45(5-6):369-79. [DOI:10.1002/elps.202300131]

40. Scarsella L, Ehrke-Schulz E, Paulussen M, Thal SC, Ehrhardt A, Aydin M. Advances of recombinant adenoviral vectors in preclinical and clinical applications. Viruses. 2024;16(3):377. [DOI:10.3390/v16030377]

41. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007- an update. J Gene Med. 2007;9(10):833-42. [DOI:10.1002/jgm.1100]

42. Edelstein M, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med. 2004;6(6):597-602. [DOI:10.1002/jgm.619]

43. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012- an Update. J Gene Med. 2013;15(2):65-77. [DOI:10.1002/jgm.2698]

44. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018;20(5):3015. [DOI:10.1002/jgm.3015]

45. Ginn SL, Mandwie M, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2023- an update. J Gene Med. 2024;26(8):3721. [DOI:10.1002/jgm.3721]

46. Ma C-C, Wang Z-L, Xu T, He Z-Y, Wei Y-Q. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv. 2020:40:107502. [DOI:10.1016/j.biotechadv.2019.107502]

47. Salauddin M, Saha S, Hossain MG, Okuda K, Shimada M. Clinical application of adenovirus (AdV): A comprehensive review. Viruses. 2024;16(7):1094. [DOI:10.3390/v16071094]

48. Muravyeva A, Smirnikhina S. Adenoviral vectors for gene therapy of hereditary diseases. Biology. 2024;13(12):1052. [DOI:10.3390/biology13121052]

49. Bramson J, Graham F, Gauldie J. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin Biotechnol. 1995;6(5):590-5. [DOI:10.1016/0958-1669(95)80097-2]

50. Muravyeva A, Smirnikhina S. Strategies for modifying adenoviral vectors for gene therapy. Int J Mol Sci. 2024;25(22):12461. [DOI:10.3390/ijms252212461]

51. Yei S, Mittereder N, Tang K, O'Sullivan C, Trapnell BC. Adenovirus-mediated gene transfer for cystic fibrosis: Quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1994:1:192-200.

52. Hauser MA, Amalfitano A, Kumar‐Singh R, Hauschka SD, Chamberlain JS. Improved adenoviral vectors for gene therapy of duchenne muscular dystrophy. Neuromuscul Disord. 1997;7(5):277-83. [DOI:10.1016/S0960-8966(97)00052-7]

53. Singhal S, Kaiser LR. Cancer chemotherapy using suicide genes. Surg Oncol Clin N Am. 1998;7(3):505-36. [DOI:10.1016/S1055-3207(18)30258-8]

54. Amessou M, Kandouz M. Targeting intercellular communication in cancer gene therapy. Novel Gene Therapy Approaches. 2013. [DOI:10.5772/54860]

55. Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist. 2002;7(1):46-59. [DOI:10.1634/theoncologist.7-1-46]

56. Rosenfeld ME, Feng M, Michael SI, Siegal GP, Alvarez RD, Curiel DT. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin Cancer Res. 1995;1(12):1571-80.

57. Bonnekoh B, Greenhalgh DA, Bundman DS, Kosai K, Chen SH, Finegold MJ, et al. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer in vivo for treatment of experimental human melanoma. J Invest Dermatol. 1996;106(6):1163-8. [DOI:10.1111/1523-1747.ep12347786]

58. Shaw AR, Suzuki M. Immunology of adenoviral vectors in cancer therapy. Mol Ther Methods Clin Dev. 2019:15:418-29. [DOI:10.1016/j.omtm.2019.11.001]

59. Gandhi MK, Khanna R. Viruses and Lymphoma. Pathology. 2005;37(6):420-33. [DOI:10.1080/003130200500368303]

60. Zhang C, Zhou D. Adenoviral vectorbased strategies against infectious disease and cancer. Hum Vaccin Immunother. 2016;12(8):2064-74. [DOI:10.1080/21645515.2016.1165908]

61. Shin S-P, Seo H-H, Shin J-H, Park H-B, Lim D-P, Eom H-S, et al. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. Mol Ther. 2013;21(3):688-95. [DOI:10.1038/mt.2012.252]

62. Sato-Dahlman M, LaRocca C, Yanagiba C, Yamamoto M. Adenovirus and immunotherapy: Advancing cancer treatment by combination. Cancers. 2020;12(5):1295. [DOI:10.3390/cancers12051295]

63. Meng Y, Liu H, Zhu H, Zhang W, Sun D, Han X, et al. RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment. J Immunother Cancer. 2024;12(1):007171. [DOI:10.1136/jitc-2023-007171]

64. Biegert G, Shaw AR, Suzuki M. Current development in adenoviral vectors for cancer immunotherapy. Mol Ther Oncolytics. 2021:23:571-81. [DOI:10.1016/j.omto.2021.11.014]

65. Mantwill K, Klein FG, Wang D, Hindupur SV, Ehrenfeld M, Holm PS, et al. Concepts in oncolytic adenovirus therapy. Int J Mol Sci. 2021;22(19):10522. [DOI:10.3390/ijms221910522]

66. Tripodi L, Vitale M, Cerullo V, Pastore L. Oncolytic adenoviruses for cancer therapy. Int J Mol Sci. 2021;22(5):2517. [DOI:10.3390/ijms22052517]

67. Liang M. Oncorine, the world's first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18(2):171-6. [DOI:10.2174/1568009618666171129221503]

68. Seemann S, Maurici D, Olivier M, Caron de Fromentel C, Hainaut P. The tumor suppressor gene TP53: Implications for cancer management and therapy. Crit Rev Clin Lab Sci. 2004;41(5-6):551-83. [DOI:10.1080/10408360490504952]

69. Boyle JO, Hakim J, Koch W, Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993;53(19):4477-80.

70. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res. 1992;52(21):5997-6000.

71. Gleich LL. Gene therapy for head and neck cancer. The Laryngoscope. 2000;110(5):708-26. [DOI:10.1097/00005537-200005000-00002]

72. Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther. 2004;10(4):616-29. [DOI:10.1016/j.ymthe.2004.07.013]

73. Coughlan L. Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines. Front Immunol. 2020:11:909. [DOI:10.3389/fimmu.2020.00909]

74. Feng S, Bibi S, Aley PK, Cappuccini F, Clutterbuck EA, Conlin K, et al. Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study. J Infect. 2025;90(2):106423. [DOI:10.1016/j.jinf.2025.106423]

75. Coughlan L, Mullarkey C, Gilbert S. Adenoviral vectors as novel vaccines for influenza. J Pharm Pharmacol. 2015;67(3):382-99. [DOI:10.1111/jphp.12350]

76. Bera A, Sen D. Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases. Heart Fail Rev. 2017;22(6):795-823. [DOI:10.1007/s10741-017-9622-7]

77. Dedieu JF, Mahfoudi A, Le Roux A, Branellec D. Vectors for gene therapy of cardiovascular disease. Curr Cardiol Rep. 2000;2(1):39-47. [DOI:10.1007/s11886-000-0024-3]

78. Schwartze Jt, Havenga M, Bakker Wam, Bradshaw Ac, Nicklin Sa. Adenoviral vectors for cardiovascular gene therapy applications: A clinical and industry perspective. J Mol Med. 2022;100(6):875-901. [DOI:10.1007/s00109-022-02208-0]

79. Zacchigna S, Zentilin L, Giacca M. Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circ Res. 2014;114(11):1827-46. [DOI:10.1161/CIRCRESAHA.114.302331]

80. Nikrad JA, Galvin RT, Sheehy MM, Novacek EL, Jacobsen KL, Corbière SMAS, et al. Conditionally replicative adenovirus as a therapy for malignant peripheral nerve sheath tumors. Mol Ther Oncol. 2024;32(2):200783. [DOI:10.1016/j.omton.2024.200783]

81. Harvey AR, Hellström M, Rodger J. Gene therapy and transplantation in the retinofugal pathway. Prog Brain Res. 2009:175:151-61. [DOI:10.1016/S0079-6123(09)17510-6]

82. Barcia C, JimenezDalmaroni M, Kroeger KM, Puntel M, Rapaport AJ, Larocque D, et al. One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: Clinical implications. Mol Ther. 2007;15(12):2154-63. [DOI:10.1038/sj.mt.6300305]

83. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 2008;21(4):704-15. [DOI:10.1128/CMR.00052-07]

84. Vu A, McCray PB. New directions in pulmonary gene therapy. Hum Gene Ther. 2020;31(17-18):921-39. [DOI:10.1089/hum.2020.166]

85. Maggio I, Stefanucci L, Janssen JM, Liu J, Chen X, Mouly V, et al. Selection-free gene repair after adenoviral vector transduction of designer nucleases: Rescue of dystrophin synthesis in DMD muscle cell populations. Nucleic Acids Res. 2016;44(3):1449-70. [DOI:10.1093/nar/gkv1540]

86. Clemens PR, Kochanek S, Sunada Y, Chan S, Chen HH, Campbell KP, et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 1996;3(11):965-72.

87. Chuah MK, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia a following gene therapy with highcapacity adenoviral vectors. Blood. 2003;101(5):1734-43. [DOI:10.1182/blood-2002-03-0823]

88. Thorrez L, VandenDriessche T, Collen D, Chuah MK. Preclinical gene therapy studies for hemophilia using adenoviral vectors. Semin Thromb Hemost. 2004;30(2):173-83. [DOI:10.1055/s-2004-825631]

89. Chuah MK, Collen D, VandenDriessche T. Gene therapy for hemophilia. J Gene Med. 2001;3(1):3-20. https://doi.org/10.1002/1521-2254(200101/02)3:1<3::AID-JGM167>3.0.CO;2-H [DOI:10.1002/1521-2254(200101/02)3:13.0.CO;2-H]

90. Stephens C, Lauron E, Kashentseva E, Lu Z, Yokoyama W, Curiel D. Long‐term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9. J Control Release. 2019:298:128-41. [DOI:10.1016/j.jconrel.2019.02.009]

91. Hu C, Cela RG, Suzuki M, Lee B, Lipshutz GS. Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proc Natl Acad Sci USA. 2011;108(5):2082-7. [DOI:10.1073/pnas.1015571108]

92. Shiratori Y, Kanai F, Ohashi M, Omata M. Strategy of liver‐directed gene therapy: Present status and future Prospects. Liver. 1999;19(4):265-74. [DOI:10.1111/j.1478-3231.1999.tb00048.x]

93. Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, et al. Correction of enzymatic and lysosomal storage defects in fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther. 1999;10(10):1667-82. [DOI:10.1089/10430349950017671]

94. Stephens CJ, Kashentseva EA, Everett W, Kaliberova LN, Curiel DT. Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9. Gene Ther. 2018:25(2):139-56. [DOI:10.1038/s41434-018-0003-1]

95. Kay MA, Graham F, Leland F, Woo SL. Therapeutic serum concentrations of human alpha‐1‐antitrypsin after adenoviral‐mediated gene transfer into mouse hepatocytes. Hepatology. 1995;21(3):815-9. [DOI:10.1002/hep.1840210331]

96. Ye X, Robinson MB, Batshaw ML, Furth EE, Smith I, Wilson JM. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem. 1996;271(7):3639-46. [DOI:10.1074/jbc.271.7.3639]

97. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao G-P, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1-2):148-58. [DOI:10.1016/j.ymgme.2003.08.016]

98. Morsy MA, Alford EL, Bett A, Graham FL, Caskey CT. Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J Clin Invest. 1993;92(3):1580-6. [DOI:10.1172/JCI116739]

99. Nguyen DM, Wiehle SA, Koch PE, Branch C, Yen N, Roth JA, et al. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther. 1997;4(3):191-8.

100. Melhem MF, Law JC, Ashmawy L, Johnson JT, Landreneau RJ, Srivastava S, et al. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol. 1995;146(5):1170-7.

101. Hamada K, Alemany R, Alemany R, Zhang W, Zhang W, Hittelman W, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996;56(13):3047-54.

102. Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, et al. Adenovirus-mediated wildtype p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol. 1998;5(8):681-8. [DOI:10.1007/BF02303477]

103. Sasaki Y, Morimoto I, Ishida S, Yamashita T, Imai K, Tokino T. Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: Potential application to gene therapy of colorectal cancer. Gene Ther. 2001;8(18):1401-8. [DOI:10.1038/sj.gt.3301538]

104. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res. 2001;61(24):8743-50.

105. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 1997;4(4):222-8.

106. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther. 2003;7(6):851-8. [DOI:10.1016/S1525-0016(03)00100-X]

107. Tseha ST. Role of adenoviruses in cancer therapy. Front Oncol. 2022:12:772659. [DOI:10.3389/fonc.2022.772659]

108. Xu C, Chen L, Liu G, Xu J, Lv W, Gao X, et al. Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy. Cell Rep Med. 2025;6(5):102078. [DOI:10.1016/j.xcrm.2025.102078]

109. Alemany R. Oncolytic adenoviruses in cancer treatment. Biomedicines. 2014;2(1):36-49. [DOI:10.3390/biomedicines2010036]

110. Roth JA, Grammer SF. Gene Therapy-Tumour‐Suppressor Gene Replacement/Oncogene Suppression. The Cancer Handbook. 2005. [DOI:10.1002/0470025077.chap98]

111. Ries S, Korn WM. ONYX-015: Mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer. 2002;86(1):5-11. [DOI:10.1038/sj.bjc.6600006]

112. Guo J, Mondal M, Zhou D. Development of novel vaccine vectors: Chimpanzee adenoviral vectors. Hum Vaccin Immunother. 2018;14(7):1679-85. [DOI:10.1080/21645515.2017.1419108]

113. Chavda VP, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S, et al. Adenoviral vector-based vaccine platform for COVID-19: Current status. Vaccines. 2023;11(2):432. [DOI:10.3390/vaccines11020432]

114. Grewe I, Friedrich M, Dieck M-L, Spohn M, Ly ML, Krähling V, et al. MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity. Front Immunol. 2024:15:1500615. [DOI:10.3389/fimmu.2024.1500615]

115. Sharma R, Kumar S, Kumar K. Computational biology in drug discovery and repurposing. First Edition: Apple Academic Press; 2024. [DOI:10.1201/9781003455424]

116. Mei D. Molecular mechanisms of ATP-modulated liquid-liquid phase separation (LLPS) of TDP-43 and SARS-COV-2 nucleocapsid protein. ProQuest. 2022:30340018.

117. Golan MS, Trump BD, Cegan JC, Linkov I. The vaccine supply chain: A call for resilience analytics to support COVID-19 vaccine production and distribution. arXiv. 2011:14231.

118. Mendonça SA, Lorincz R, Boucher P, Curiel DT. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines. 2021:6:97. [DOI:10.1038/s41541-021-00356-x]

119. Jacob-Dolan C, Barouch DH. COVID-19 vaccines: Adenoviral vectors. Annu Rev Med. 2022:73:41-54. [DOI:10.1146/annurev-med-012621-102252]

120. Ryan FJ, Norton TS, McCafferty C, Blake SJ, Stevens NE, James J, et al. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. Cell Rep Med. 2023;4(3):100971. [DOI:10.1016/j.xcrm.2023.100971]

121. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78. [DOI:10.1016/S0140-6736(20)31604-4]

122. Pekarek MJ, Madapong A, Wiggins J, Weaver EA. Adenoviral-vectored multivalent vaccine provides durable protection against influenza B viruses from Victoria-like and Yamagata-like lineages. Int J Mol Sci. 2025;26(4):1538. [DOI:10.3390/ijms26041538]

123. Sheehy SH, Duncan CJA, Elias SC, Choudhary P, Biswas S, Halstead FD, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012;20(12):2355-68. [DOI:10.1038/mt.2012.223]

124. Sheehy SH, Duncan CJA, Elias SC, Collins KA, Ewer KJ, Spencer AJ, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther. 2011;19(12):2269-76. [DOI:10.1038/mt.2011.176]

125. Kapulu MC, Da DF, Miura K, Li Y, Blagborough AM, Churcher TS, et al. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum. Sci Rep. 2015:5:11193. [DOI:10.1038/srep11193]

126. Longley RJ, Halbroth BR, Salman AM, Ewer KJ, Hodgson SH, Janse CJ, et al. Assessment of the Plasmodium falciparum preerythrocytic antigen UIS3 as a potential candidate for a malaria vaccine. Infect Immun. 2017;85(3):00641-16. [DOI:10.1128/IAI.00641-16]

127. Limbach KJ, Richie TL. Viral vectors in malaria vaccine development. Parasite Immunol. 2009;31(9):501-19. [DOI:10.1111/j.1365-3024.2009.01141.x]

128. Shoushtari M, Roohvand F, Salehi-Vaziri M, Arashkia A, Bakhshi H, Azadmanesh K. Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses. Hum Vaccin Immunother. 2022;18(5):2079323. [DOI:10.1080/21645515.2022.2079323]

129. Sacherl J, Kosinska A, Kemter K, Kächele M, Laumen SC, Kerth HA, et al. A thermostable therapeutic vaccine is able to break immune tolerance in a mouse model of chronic hepatitis B. JHEP Reports. 2022;5(6):100603. [DOI:10.1016/j.jhepr.2022.100603]

130. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectoris. J Am Coll Cardiol. 2005;45(7):982-8. [DOI:10.1016/j.jacc.2004.12.068]

131. Giacca M, Zacchigna S. VEGF gene therapy: Therapeutic angiogenesis in the clinic and beyond. Gene Ther. 2012;19(6):622-9. [DOI:10.1038/gt.2012.17]

132. Barkats M, Bilang-Bleuel A, Buc-Caron MH, Castel-Barthe MN, Corti O, Finiels F, et al. Adenovirus in the brain: Recent advances of gene therapy for neurodegenerative diseases. Prog Neurobiol. 1998;55(4):333-41. [DOI:10.1016/S0301-0082(98)00028-8]

133. Gal L, Robert J-C, Berrard S, Ridoux V, Stratford-Perricaudet LD, Perricaudet M, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science. 1993;259(5097):988. [DOI:10.1126/science.8382374]

134. Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid β-based therapy for Alzheimer's disease: Challenges, successes and future. Signal Transduct Target Ther. 2023;8(1):248. [DOI:10.1038/s41392-023-01484-7]

135. Mashhour B, Couton D, Perricaudet M, Briand P. In vivo adenovirus-mediated gene transfer into ocular tissues. Gene Ther. 1994;1(2):122-6. [DOI:10.1016/0042-6989(95)98740-Z]

136. Mori K, Gehlbach P, Ando A, Wahlin K, Gunther V, McVey D, et al. Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies. Invest Ophthalmol Vis Sci. 2002;43(5):1610-5.

137. Pennington MR, Saha A, Painter DF, Gavazzi C, Ismail AM, Zhou X, et al. Disparate entry of adenoviruses dictates differential innate immune responses on the ocular surface. Microorganisms. 2019;7(9):351. [DOI:10.3390/microorganisms7090351]

138. Georgakopoulou A, Wang H, Kim J, Li C, Lieber A. In vivo HSC transduction in humanized mice mediated by novel capsid-modified HDAd vectors. Mol Ther Methods Clin Dev. 2025;33(2):101448. [DOI:10.1016/j.omtm.2025.101448]

139. Liu M-J, Shin S, Li N, Shigihara T, Lee Y-S, Yoon J-W, et al. Prolonged remission of diabetes by regeneration of β-cells in diabetic mice treated with recombinant adenoviral vector expressing glucagon-like peptide-1. Mol Ther. 2007;15(1):86-93. [DOI:10.1038/sj.mt.6300005]

140. Giannoukakis N, Mi Z, Rudert WA, Gambotto A, Trucco M, Robbins P. Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I. Gene Ther. 2000;7(23):2015-22. [DOI:10.1038/sj.gt.3301333]

141. Gendelman HE, Ikezu T. Neuroimmune pharmacology. First Edition; Springer Nature;2008. [DOI:10.1007/978-0-387-72573-4]

142. Hong S-S, Marotte H, Courbon G, Firestein GS, Boulanger P, Miossec P. PUMA gene delivery to synoviocytes reduces inflammation and degeneration of arthritic joints. Nat Commun. 2017;8(1):146. [DOI:10.1038/s41467-017-00142-1]

143. Madrigal JL, Stilhano R, Silva EA. Biomaterial-guided gene delivery for musculoskeletal tissue repair. Tissue Eng Part B Rev. 2017;23(4):347-61. [DOI:10.1089/ten.teb.2016.0462]

144. Grol MW, Lee BH. Gene therapy for repair and regeneration of bone and cartilage. Curr Opin Pharmacol. 2018:40:59-66. [DOI:10.1016/j.coph.2018.03.005]

145. Cucchiarini M, Madry H. Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair. Nat Rev Rheumatol. 2019;15(1):18-29. [DOI:10.1038/s41584-018-0125-2]

146. Krishnamoorthy L, Morris HL, Harding KG. Specific growth factors and the healing of chronic wounds. J Wound Care. 2001;10(5):173-8.s [DOI:10.12968/jowc.2001.10.5.26076]

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb

Iranian

Biomedical Journal